{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-000935","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2021-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.884598+00:00","generated_at":"2026-06-30T01:54:54.953601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teva Q2 2021: Revenue $3.9B, GAAP EPS $0.19, Non-GAAP EPS $0.59; guides revenue lower","bullets":["Revenue of $3.9B (up 1% YoY); GAAP diluted EPS $0.19 (vs $0.13 Q2 2020); Non-GAAP diluted EPS $0.59 (vs $0.55).","Net debt reduced by $500M to $22.7B; operating cash flow $218M, free cash flow $625M.","2021 revenue outlook cut to $16.0-16.4B (prior $16.4-16.8B) citing COVID impact; all other guidance reaffirmed: adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.","AUSTEDO sales grew YoY; AJOVY net sales $70M worldwide; Truxima US market share reached 25%.","R&D expenses $248M (GAAP), increased 10% YoY, driven by respiratory, biosimilar projects."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-000935","json":"https://secwatch.observer/filing/0001157523-21-000935.json","markdown":"https://secwatch.observer/filing/0001157523-21-000935.md","text":"https://secwatch.observer/filing/0001157523-21-000935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752321000935/0001157523-21-000935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752321000935/a52467373.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:54:54.953601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}